Search

Your search keyword '"Shiku H"' showing total 1,060 results
Start Over Author "Shiku H"
1,060 results on '"Shiku H"'

53. Atherosclerotic and hemostatic abnormalities in patients undergoing hemodialysis

Author

Esteban C. Gabazza, Yoshitaka Mori, Kazuo Izumi, Shiku H, Mitsuya Noguchi, Tsutomu Nobori, Fumihiko Kushiya, Miho Sakakura, Masakatsu Nishikawa, and Hideo Wada

Subjects
Male, medicine.medical_specialty, Pathology, Time Factors, Arteriosclerosis, medicine.medical_treatment, 030204 cardiovascular system & hematology, Thrombomodulin, Fibrinogen, Tissue plasminogen activator, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Renal Dialysis, Internal medicine, medicine, Humans, Aged, Retrospective Studies, Prothrombin time, Hemostatic Disorders, Hemostasis, medicine.diagnostic_test, business.industry, Antithrombin, Hematology, General Medicine, Middle Aged, Prothrombin Time, Female, Partial Thromboplastin Time, Hemodialysis, business, 030217 neurology & neurosurgery, Protein C, Biomarkers, medicine.drug
Abstract

Vascular events caused by atherosclerosis are the major cause of death in patients undergoing hemodialysis (HD). The relationship between the tests of atherosclerosis and hemostasis in 84 patients with HD was examined. Abnormal test results indicating the occurrence of atherosclerosis were found in 66% by the Fontaine score, in 33% by ankle blood pressures, and in 79% by aortic calcification index (ACI). When HD was prolonged, the mean Fontaine score and ACI were further increased. Particularly, the ACI tended to correlate with HD duration. The ankle-brachial index (ABI) was decreased in patients with HD duration of more than 10 years. Before HD, the plasma levels of fibrinogen, plasmin-plasmin inhibitor complex (PIC), thrombomodulin (TM), and D-dimer were increased, while the plasma levels of protein C (PC), antithrombin (AT), thrombin-antithrombin complex (TAT), and tissue plasminogen activator (tPA)-plasminogen activator inhibitor-I (PAI-I) complex (tPA-PAI-1 complex) were decreased. With prolonged HD, the plasma levels of AT and PC were decreased, while those of D-dimer were increased. The plasma levels of TAT and TPA-PAI-1 complex were significantly increased and those of PIC, soluble fibrin (SF) and D-dimer tended to be high in patients with less than 0.7 of ABI. The plasma levels of Ddimer, TPA-PAI-1 complex, TAT, PIC, and SF tended to be high in patients with more than 0.5 in ABI. These findings suggest that patients undergoing HD have progressive atherosclerosis and that this is associated with some hemostatic abnormalities.

Published
2003

55. Increased serum levels of thrombopoietin in patients with thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, or disseminated intravascular coagulation

Author

Hideo Wada, Naoyuki Katayama, Takahiro Nakasaki, Hiyoyama K, T. Kato, Nishikawa M, Minori Shimura, T. Tahara, and Shiku H

Subjects
Hemolytic anemia, Adult, Male, medicine.medical_specialty, Thrombotic thrombocytopenic purpura, Gastroenterology, Iodide Peroxidase, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Platelet, Aplastic anemia, Thrombopoietin, Disseminated intravascular coagulation, Purpura, Thrombocytopenic, Idiopathic, Purpura, Thrombotic Thrombocytopenic, business.industry, Platelet Count, food and beverages, Anemia, Aplastic, Hematology, General Medicine, Disseminated Intravascular Coagulation, Middle Aged, medicine.disease, Thrombocytopenic purpura, Schistocyte, embryonic structures, Immunology, Hemolytic-Uremic Syndrome, Female, business
Abstract

The serum levels of thrombopoietin (TPO) were measured in 16 patients with thrombotic thrombocytopenic purpura (TTP), 12 with hemolytic uremic syndrome (HUS), 10 with aplastic anemia (AA), 10 with disseminated intravascular coagulation (DIC), and 71 with idiopathic thrombocytopenic purpura (ITP). The serum TPO levels were measured with a sensitive sandwich enzyme-linked immunosorbent assay. The serum TPO level in the ITP group (1.68 +/- 0.85 fmol/ml) were not significantly increased compared with those of the normal subjects. The TPO levels in the TTP (2.77 +/- 1.38 fmol/ml) and HUS groups (5.77 +/- 4.41 fmol/ml) were higher than those of the normal subjects. The patients with AA (12.7 +/- 8.0 fmol/ml) and those with DIC (13.3 +/- 5.7 mol/ml) had significantly higher serum TPO levels than did the normal subjects and ITP patients. The TPO levels were well correlated with the platelet counts in the TTP patients, and were negatively correlated with the platelet counts in the ITP patients. These results suggest that the serum TPO levels in some thrombocytopenic diseases are regulated not only by the platelet count and the megakaryocyte mass, but also by other factors.

Published
1997

56. Increased soluble fibrin monomer and soluble thrombomodulin levels in non-insulin-dependent diabetes mellitus

Author

Hideo Wada, Mori Y, Yasuhiro Sumida, Yukihiko Adachi, Takahiro Nakasaki, Shiku H, Hiyoyama K, Yutaka Yano, Deguchi K, Masashi Fujii, and Minori Shimura

Subjects
Adult, Male, medicine.medical_specialty, endocrine system diseases, Thrombomodulin, Fibrinogen, Fibrin, Thrombin, Internal medicine, medicine, Albuminuria, Humans, Aged, Prothrombin time, medicine.diagnostic_test, biology, business.industry, Albumin, nutritional and metabolic diseases, Hematology, General Medicine, Middle Aged, medicine.disease, Endocrinology, Diabetes Mellitus, Type 2, PPIC, biology.protein, Prothrombin Time, Microalbuminuria, Female, business, Partial thromboplastin time, medicine.drug
Abstract

We measured the plasma levels of fibrinogen, D-dimer, thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), soluble fibrin monomer (SFM), tissue-type plasminogen activator (t-PA) and thrombomodulin (TM) in patients with non-insulin-dependent diabetes mellitus (NIDDM). There were no significant differences in the hemostatic parameters between the 77 patients with NIDDM and healthy control subjects, although the plasma levels of fibrinogen, D-dimer, TAT, and PPIC in the NIDDM patients were slightly higher than those in the healthy controls. Among the NIDDM patients divided into three groups by the urinary albumin excretion (UAE) level, there was no significant difference in age or sex among the normo-, micro-, and macroalbuminuria groups, and the HbA1C level in the micro- and macroalbuminuria groups were slightly higher than those in the normoalbuminuria group. There was no significant difference in activated partial thromboplastin time, prothrombin time, fibrinogen, TAT, PPIC, D-dimer, or t-PA among these three groups. The plasma SFM and TM levels in the macroalbuminuria group were significantly higher than those in the normo- and microalbuminuria groups. The relationships between HbA1C and the hemostatic parameters were poor, but the plasma TM and SFM levels were significantly correlated with the urine albumin index.

Published
1997

57. Plasma levels of activated FVII in various diseases

Author

Hiyoyama K, Deguchi K, Shiku H, Kamikura Y, Minori Shimura, Yamada A, S. Nagaya, Hideo Wada, and Mori Y

Subjects
Male, medicine.medical_specialty, Factor VIIa, Gastroenterology, Communicable Diseases, Autoimmune Diseases, Tissue factor, chemistry.chemical_compound, Pregnancy, hemic and lymphatic diseases, Internal medicine, Neoplasms, Blood plasma, Coagulopathy, Medicine, Humans, Disseminated intravascular coagulation, Factor VII, business.industry, Hematology, General Medicine, medicine.disease, Thrombocytopenic purpura, Hematologic Diseases, Coagulation, chemistry, Immunology, Female, business, Protein C, Biomarkers, medicine.drug
Abstract

Plasma activated factor VIIa (FVIIa) levels were measured in various diseases using mutant tissue factor (TF). FVIIa levels in thrombotic patients and patients with idiopathic thrombocytopenic purpura were significantly higher than those in healthy control subjects. The plasma FVIIa levels in thrombotic patients treated with warfarin were similar to those of control subjects. The plasma FVIIa levels in pregnant women and patients with systemic lupus erythematosus, infection or malignancies were high. However, the levels in patients with disseminated intravascular coagulation (DIC) were not significantly increased. DIC patients are in a severe hypercoagulable state, and exhibit severe consumption of coagulation factors. The slightly increased FVIIa level in the DIC patients observed is probably considered to be caused by consumption of coagulation factors. The plasma FVIIa level was poorly correlated with other hemostatic parameters except for protein C in our analysis of all cases. In the analysis of DIC and thrombotic patients treated without warfarin, the plasma FVIIa level was negatively correlated with TF antigen. Plasma FVIIa levels might reflect hypercoagulability in thrombotic diseases, and a normalized FVIIa level in patients with thrombotic diseases should be considered to be associated with DIC.

Published
1996

61. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients

Author

Yamaguchi, M., primary, Nakamura, N., additional, Suzuki, R., additional, Kagami, Y., additional, Okamoto, M., additional, Ichinohasama, R., additional, Yoshino, T., additional, Suzumiya, J., additional, Murase, T., additional, Miura, I., additional, Ohshima, K., additional, Nishikori, M., additional, Tamaru, J.-i., additional, Taniwaki, M., additional, Hirano, M., additional, Morishima, Y., additional, Ueda, R., additional, Shiku, H., additional, and Nakamura, S., additional

Published
2008
Full Text
View/download PDF

63. Whole‐Cell Biosensors

Author

Shiku, H., primary, Nagamine, K., additional, Kaya, T., additional, Yasukawa, T., additional, and Matsue, T., additional

Published
2008
Full Text
View/download PDF

69. PRIMARY HYDATIDOSIS OF THE THIGH

Author

Syed Sa, Mine R, Fujii T, Nakayama E, and Shiku H

Subjects
Immune system, business.industry, Immunology, Medicine, Surgery, business
Published
1999

72. Ileocolonic Lymphomas: A Series of 16 Cases

Author

Saito, T., primary, Toyoda, H., additional, Yamaguchi, M., additional, Nakamura, T., additional, Nakamura, S., additional, Mukai, K., additional, Fuke, H., additional, Wakita, Y., additional, Iwata, M., additional, Adachi, Y., additional, and Shiku, H., additional

Published
2005
Full Text
View/download PDF

84. Antileukemia multifunctionality of CD4+T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer

Author

Fujiwara, H, Ochi, T, Ochi, F, Miyazaki, Y, Asai, H, Narita, M, Okamoto, S, Mineno, J, Kuzushima, K, Shiku, H, and Yasukawa, M

Abstract

To develop gene-modified T-cell-based antileukemia adoptive immunotherapy, concomitant administration of CD4+and CD8+T cells that have been gene modified using identical HLA class I-restricted leukemia antigen-specific T-cell receptor(TCR) gene transfer has not yet been fully investigated. Here, using CD4+and CD8+T cells that had been gene modified with a retroviral vector expressing HLA-A*24:02-restricted and Wilms’ tumor 1 (WT1)-specific TCR-α/βgenes and siRNAsfor endogenous TCRs (WT1-siTCR/CD4+T cells and WT1-siTCR/CD8+T cells), we examined the utility of this strategy. WT1-siTCR/CD4+T cells sufficiently recognized leukemia cells in an HLA class I-restricted manner and provided target-specific Th1 help for WT1-siTCR/CD8+T cells. By using a xenografted mouse model, we found that WT1-siTCR/CD4+T cells migrated to leukemia sites and subsequently attracted WT1-siTCR/CD8+T cells via chemotaxis. Therapy-oriented experiments revealed effective enhancement of leukemia suppression mediated by concomitant administration of WT1-siTCR/CD4+T cells and WT1-siTCR/CD8+T cells. Importantly, this augmented efficacy in the presence of WT1-siTCR/CD4+T cells was correlated with longer survival and enhanced formation of memory T cells by WT1-siTCR/CD8+T cells. Collectively, our experimental findings strongly suggest that this strategy would be clinically advantageous for the treatment of human leukemia.

Published
2015
Full Text
View/download PDF

87. Hemostatic markers in Japanese patients undergoing anticoagulant therapy under thrombo-test monitoring

Author

Ikuma, H., primary, Wada, H., additional, Mori, Y., additional, Shimura, M., additional, Hiyoyama, K., additional, Nakasaki, T., additional, Nishikawa, M., additional, Onoda, K., additional, Yamada, N., additional, Ohta, T., additional, Nishioka, J., additional, Nobori, T., additional, Gabazza, E. C., additional, Sakuragawa, N., additional, and Shiku, H., additional

Published
1999
Full Text
View/download PDF

90. Complex Gangliosides are Essential in Spermatogenesis of Mice

Author

Takamiya, K., primary, Yamamoto, A., additional, Furukawa, K., additional, Zhao, J., additional, Fukumoto, S., additional, Yamashiro, S., additional, Okada, M., additional, Haraguchi, M., additional, Shin, M., additional, Kishikawa, M., additional, Shiku, H., additional, and Aizawa, S., additional

Published
1999
Full Text
View/download PDF

92. Bone marrow-derived dendritic cells incorporate and process hydrophobized polysaccharide/oncoprotein complex as antigen presenting cells.

Author

Wang, L, primary, Ikeda, H, additional, Ikuta, Y, additional, Schmitt, M, additional, Miyahara, Y, additional, Takahashi, Y, additional, Gu, X, additional, Nagata, Y, additional, Sasaki, Y, additional, Akiyoshi, K, additional, Sunamoto, J, additional, Nakamura, H, additional, Kuribayashi, K, additional, and Shiku, H, additional

Published
1999
Full Text
View/download PDF

94. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation

Author

Yamamuro, M., primary, Wada, H., additional, Kumeda, K., additional, Inoue, A., additional, Tsuji, I., additional, Nakasaki, T., additional, Shimura, M., additional, Hiyoyama, K., additional, Gabazza, E. C., additional, Nishikawa, M., additional, Deguchi, K., additional, Shiku, H., additional, and Kato, H., additional

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results